- Home
- UGRO vs TOVX Comparison
UGRO vs TOVX Comparison
Compare UGRO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- TOVX
- Stock Information
- Founded
- UGRO 2014
- TOVX 2001
- Country
- UGRO United States
- TOVX United States
- Employees
- UGRO N/A
- TOVX N/A
- Industry
- UGRO Industrial Specialties
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- TOVX Health Care
- Exchange
- UGRO Nasdaq
- TOVX Nasdaq
- Market Cap
- UGRO 3.8M
- TOVX 4.5M
- IPO Year
- UGRO N/A
- TOVX 2006
- Fundamental
- Price
- UGRO $0.40
- TOVX $0.42
- Analyst Decision
- UGRO Strong Buy
- TOVX Hold
- Analyst Count
- UGRO 1
- TOVX 1
- Target Price
- UGRO $3.00
- TOVX N/A
- AVG Volume (30 Days)
- UGRO 3.2M
- TOVX 1.2M
- Earning Date
- UGRO 09-02-2025
- TOVX 08-11-2025
- Dividend Yield
- UGRO N/A
- TOVX N/A
- EPS Growth
- UGRO N/A
- TOVX N/A
- EPS
- UGRO N/A
- TOVX N/A
- Revenue
- UGRO $59,985,138.00
- TOVX N/A
- Revenue This Year
- UGRO N/A
- TOVX N/A
- Revenue Next Year
- UGRO $31.25
- TOVX N/A
- P/E Ratio
- UGRO N/A
- TOVX N/A
- Revenue Growth
- UGRO N/A
- TOVX N/A
- 52 Week Low
- UGRO $0.26
- TOVX $0.37
- 52 Week High
- UGRO $1.92
- TOVX $7.15
- Technical
- Relative Strength Index (RSI)
- UGRO 50.65
- TOVX 44.90
- Support Level
- UGRO $0.31
- TOVX $0.45
- Resistance Level
- UGRO $0.42
- TOVX $0.47
- Average True Range (ATR)
- UGRO 0.07
- TOVX 0.04
- MACD
- UGRO -0.00
- TOVX 0.00
- Stochastic Oscillator
- UGRO 35.71
- TOVX 31.76
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.